Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T13:30:30.410Z.
Calculation as of: 2026-10-06T13:30:30.410Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a397cd850420951a0c9724a6b76f21fabdb26d17d869f1b33831b183cdf643d3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$2.32M
PS Ratio
774.20
TTM Avg
1295.61
3Y Avg
740.97
5Y Avg
482.27
Market Cap
$1.50M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.49M
PS Ratio
0.58
TTM Avg
0.50
3Y Avg
18956497.95
5Y Avg
18956497.95
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Autonomix Medical, Inc. (AMIX) | $1.92M | N/A | N/A | N/A | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.93M | 0.11 | 0.09 | 0.25 | 0.61 |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | 774.20 | 1295.61 | 740.97 | 482.27 |
| Curis, Inc. (CRIS)vs › | $1.50M | 0.35 | 1.36 | 2.70 | 8.10 |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.50M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.22M | N/A | 1.63 | 5.61 | 81.97 |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | 0.58 | 0.50 | 18956497.95 | 18956497.95 |
| INVO Fertility, Inc. (IVF)vs › | $1.45M | 0.19 | 0.23 | 0.46 | 3.45 |
| iTonic Holdings Ltd. (ITOC)vs › | $2.38M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.38M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q2 FY2026Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-12 |
| Q3 FY2026Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q4 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-27 |
| Q1 FY2027Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-13 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
